semaglutide bad for kidneys in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide cuts kidney risk in

What do you hope your colleagues take away from the paper and this conversation

Berberine offers promising metabolic benefits, including improved glucose control and lipid profiles, supported by preliminary clinical and mechanistic studies

Our findings suggest that direct activation of GLP-1R by Ex-4 reduces OA-induced steatosis in HepG2 cells by reducing fatty acid uptake and transport via FABP1 downregulation

To date, the trial has enrolled 94 participants, with 54 in the T2DM group and 40 in the obesity group

Some even report feeling energized enough to have more productive afternoons following their injection.

Risk factors include female gender, increased age, cardiovascular disease, diabetes mellitus, constipation, irritable bowel syndrome, thrombophilia, history of abdominal aortic aneurysm repair, constipation-inducing drugs, immunomodulators, and other illicit drug use [1,2,3]